濟民製藥(603222.SH):向新友誼醫院提供不超1500萬元財務資助
格隆匯 1 月 22日丨 濟民製藥(603222.SH)公佈,公司向控股子公司新友誼醫院提供不超過人民幣1500萬元的財務資助,年利率為5.22%,借款期限為36個月,相關款項將用於新友誼醫院南擴建設項目。
新友誼醫院南擴建設項目尚處於土地拆遷過程中,具體建設項目尚未規劃,後期的項目建設目前尚無法確定,敬請廣大投資者關注投資風險。
新友誼醫院2020年度財務數據正在審計過程中,若新友誼醫院業績較差或虧損,根據前期協議約定,邵品將面臨剩餘15.51%股權補償及較大金額的現金補償,公司能否按時收到現金補償款存在較大不確定性,屆時,公司將採取法律措施維護公司利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.